Alterity Therapeutics (ASXATH) has unveiled a new commercial assessment of its lead candidate ATH434, positioning the therapy as a potential first-in-class treatment for Multiple System Atrophy, a rare and debilitating Parkinsonian disorder with no approved therapies. …
Alterity Therapeutics targets major market with ATH434 in Multiple System Atrophy
September 29, 2025 Australian Biotech
Latest Video
New Stories
-
The symptoms have been identified, but the widely held belief about the cause is a miss
September 30, 2025 - - Latest News -
UK companies are granted more time to decide on pricing agreement
September 29, 2025 - - Latest News -
Anatara strengthens board with the appointment of Dirk van Dissel
September 29, 2025 - - Australian Biotech -
CLINUVEL advances next-generation peptide drug formulations
September 29, 2025 - -
Alterity Therapeutics targets major market with ATH434 in Multiple System Atrophy
September 29, 2025 - - Australian Biotech -
Lower than expected uptake of new therapies impacts PBS spend
September 29, 2025 - - Latest News -
Chimeric reports encouraging early data from CHM CDH17 trial
September 29, 2025 - - Australian Biotech